Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 17/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.44 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.44 |
| ▸ | PSMD11 | O00231 | 1/20 | 0.44 |
| ▸ | PSMD12 | O00232 | 1/20 | 0.44 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.44 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.44 |
| ▸ | PSMD3 | O43242 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | PSMC3 | P17980 | 1/20 | 0.44 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.44 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.44 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.44 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.44 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.44 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.44 |
| ▸ | PSMA4 | P25789 | 1/20 | 0.44 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19249338 | 0.96 | OPRK1 (0.58) | OPRK1OPRM1 | |
| SCHEMBL11931476 | 0.96 | OPRK1 (0.58) | OPRK1OPRM1 | |
| SCHEMBL22957114 | 0.94 | OPRK1 (0.56) | OPRK1OPRM1 | |
| SCHEMBL21886579 | 0.92 | OPRK1 (0.58) | OPRK1OPRM1 | |
| SCHEMBL17132175 | 0.91 | OPRK1 (0.58) | OPRK1OPRM1 | |
| SCHEMBL12317349 | 0.90 | OPRK1 (0.59) | OPRK1OPRM1 | |
| SCHEMBL21286615 | 0.90 | OPRK1 (0.59) | OPRK1OPRM1 | |
| SCHEMBL11931981 | 0.88 | OPRK1 (0.62) | OPRK1OPRM1 | |
| SCHEMBL25729800 | 0.87 | OPRK1 (0.68) | OPRK1OPRM1 | |
| SCHEMBL21886580 | 0.85 | OPRK1 (0.63) | OPRK1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210346505-A1 | Oral Formulations of Kappa Opioid Receptor Agonists | CARA THERAPEUTICS, INC. | 2021-11-11 | — | — | US | disclosed |
| US-11083726-B2 | Methods and compositions for treating vasomotor symptoms | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2021-08-10 | — | — | US | disclosed |
| US-20210030745-A9 | Methods and Compositions for Treating Vasomotor Symptoms | ACER THERAPEUTICS INC. | 2021-02-04 | — | — | US | disclosed |
| US-20190255037-A1 | Methods and Compositions for Treating Vasomotor Symptoms | UNIV WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346505-A1 | Oral Formulations of Kappa Opioid Receptor Agonists | OPRK1, OPRL1, OGFR | OPRK1 1/4885OPRM1 5/4885PSMB5 2240/4885 |
| US-20210030745-A9 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | OPRK1 554/4885OPRM1 814/4885PSMB5 4100/4885 |
| US-20190255037-A1 | Methods and Compositions for Treating Vasomotor Symptoms | VASP, PDE3A, PDE2A | OPRK1 554/4885OPRM1 814/4885PSMB5 4100/4885 |
| US-11083726-B2 | Methods and compositions for treating vasomotor symptoms | VASP, PDE3A, PDE2A | OPRK1 554/4885OPRM1 814/4885PSMB5 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.